NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.